In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

The company recently closed a $7 million funding round and added to its executive team as it aims for a 2017 launch for its test.

Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.

The urine-based test is designed to identify men at high risk for aggressive prostate cancer, as well as those at low risk for the disease.

The company's diagnostic is being used to determine the eligibility of patients with solid tumors to participate in a Phase II trial of entrectinib.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.

Short tandem repeat and expression data indicate that the U87MG cell line in the ATCC collection no longer represents the glioma from which it was established.

Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests. 

Unlike existing versions, CLARK-S allows mismatches between sample reads and reference databases, enabling it to map a larger proportion of input sequences.

The software combines the output of multiple data projection methods with gene signature information to help users identify meaningful biological processes.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Using a sixth century sample from Germany, researchers reconstructed a high-coverage genome sequence for the Yersinia pestis strain involved in the Justinian plague. 

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

The funding will support nine projects investigating why Alzheimer's disease disproportionately affects women versus men.

A University of Toronto team developed the probes to improve upon its previously described electrochemical clamp assay technology.

Nobel Prize-winning chemist Roger Tsien died on Aug. 24 in Eugene, Oregon. He was professor of pharmacology, chemistry, and biochemistry at the University of California San Diego School of Medicine. His work on illuminating life within living cells through the discovery and development of green fluorescent protein derived from the jellyfish Aequorea victoria led him to co-win the 2008 Nobel in chemistry. That work was done in collaboration with Osamu Shimomura and Martin Chalfie.

HTG Molecular Diagnostics has appointed Ann Hanham to its board of directors. Hanham is a founding and managing partner of BAR Capital Management. She currently serves on two other public company boards, and has served on the boards of 20 global companies, both private and public. From February 2000 to November 2013, she served as managing director and general partner of Burrill & Company.  Prior to that, Hanham held positions in clinical and regulatory affairs, and product development at various companies, including InterMune, Otsuka America Pharmaceuticals, Celtrix Pharmaceuticals, and Becton Dickinson.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.

Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.

The clinical laboratory has designed a hereditary cancer risk gene panel capable of detecting both SNVs and CNVs without requiring an orthogonal validation test. 

The company has launched a beta version of its clinical trial matching service, and is helping patients learn about precision medicine and find others with similar tumor profiles. 

Mass spec-based analysis of CFS patients shows an analyte signature indicative of a stalled, underperforming metabolism, and could help diagnose the condition.

Researchers from the diagnostics company will work with researchers from the microbial genomics lab of George Weinstock.

The proteomic test identifies prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy.